First Patient Dosed in Phase 3 REVEAL Trial of ION582 for Angelman Syndrome
The Pharma Data
JUNE 11, 2025
This mechanism has the potential to partially restore UBE3A protein production in neurons, addressing the root cause of the disorder. Encouraging results from the previously completed Phase 1/2 HALOS study support the continued development of ION582.
Let's personalize your content